Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Forest Labs Expects “Modest” Lexapro Gain From Generic Zoloft Launch

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Company expects Lexapro to continue to gain ground in SSRI market although promotional spend will not increase significantly.

You may also be interested in...



Lexapro Scripts Hold Up Against Competition From Generic Zoloft

Forest's antidepressant shows prescription growth in September, despite August entry of generic Zoloft.

Lexapro Scripts Hold Up Against Competition From Generic Zoloft

Forest's antidepressant shows prescription growth in September, despite August entry of generic Zoloft.

Forest’s Lexapro Retains Exclusivity In Case With Teva

The Forest breadwinner will enjoy patent protection into 2012 following a Delaware federal court decision July 13.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By